Pharmakure Ltd.
Clinical-stage precision-medicine company developing whole-blood biomarker assays to detect oligomeric pathological proteins and using those assays to select and validate repurposed drug combinations in translational and clinical studies for neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Pharmakure Ltd.
PharmaKure Ltd, Alderley Park, Congleton Road, Nether Alderley, Open Access Lab 19S6, Macclesfield, SK10 4TG, United Kingdom
Patents
Products
Combination therapy candidate targeting amyloid-β oligomers (repurposed drugs)
A combination of repurposed compounds formulated to reduce or eliminate toxic amyloid-β oligomers for early-stage Alzheimer's disease evaluation.
Combination therapy candidate targeting α‑synuclein aggregates (repurposed drugs)
A repurposed‑drug combination developed to break down pathological α‑synuclein aggregates and prevent new aggregate formation for synucleinopathies including Parkinsonian disorders and MSA.
Whole-blood assay for amyloid-β oligomers
Companion-diagnostic assay that detects cell-associated oligomeric amyloid-β in whole blood for diagnosis, monitoring and trial enrollment in Alzheimer's research.
Whole-blood assay for α‑synuclein oligomers
Companion-diagnostic assay that detects cell-associated oligomeric α‑synuclein in whole blood to support diagnosis, monitoring and patient stratification in synucleinopathy studies.
Combination therapy candidate targeting amyloid-β oligomers (repurposed drugs)
A combination of repurposed compounds formulated to reduce or eliminate toxic amyloid-β oligomers for early-stage Alzheimer's disease evaluation.
Combination therapy candidate targeting α‑synuclein aggregates (repurposed drugs)
A repurposed‑drug combination developed to break down pathological α‑synuclein aggregates and prevent new aggregate formation for synucleinopathies including Parkinsonian disorders and MSA.
Whole-blood assay for amyloid-β oligomers
Companion-diagnostic assay that detects cell-associated oligomeric amyloid-β in whole blood for diagnosis, monitoring and trial enrollment in Alzheimer's research.
Whole-blood assay for α‑synuclein oligomers
Companion-diagnostic assay that detects cell-associated oligomeric α‑synuclein in whole blood to support diagnosis, monitoring and patient stratification in synucleinopathy studies.
Services
Collaborative development, laboratory validation and clinical study validation of whole-blood assays for oligomeric disease proteins to support diagnosis, monitoring and trial enrollment.
Design and execution of biomarker-integrated Phase 2a/2b clinical studies including dose-escalation and cohort stratification using blood-based biomarker endpoints.
Collaborative development, laboratory validation and clinical study validation of whole-blood assays for oligomeric disease proteins to support diagnosis, monitoring and trial enrollment.
Design and execution of biomarker-integrated Phase 2a/2b clinical studies including dose-escalation and cohort stratification using blood-based biomarker endpoints.
Expertise Areas
- Biomarker discovery and blood-based diagnostic assay development
- Translational pharmacology and ex‑vivo drug screening
- Clinical trial design and management with integrated biomarkers
- Drug repurposing and combination therapy development
Key Technologies
- Whole-blood oligomer detection assays
- Cell-associated oligomer enrichment methods
- Immunoassay platforms (ELISA-type) for protein oligomers
- Machine learning for multimodal biomarker integration
News & Updates
Sponsorship of a Multiple Systems Atrophy research symposium to support scientific exchange on MSA.
Announcement of a move of company headquarters to a new health-focused facility in Didsbury, Manchester.
Initiation of a clinical study to identify and validate blood-based biomarkers for Alzheimer's disease using whole-blood assays.
Signed a letter of intent for potential commercial collaboration to secure access to external assays for measuring aggregated amyloid‑β and α‑synuclein in blood.
Regulatory authorisation granted by the UK regulator for clinical evaluation of a repurposed-drug combination targeting amyloid pathology.
Collaboration to investigate epigenetic mechanisms relevant to Alzheimer's disease risk and earlier interventions.
Sponsorship of a Multiple Systems Atrophy research symposium to support scientific exchange on MSA.
Announcement of a move of company headquarters to a new health-focused facility in Didsbury, Manchester.
Initiation of a clinical study to identify and validate blood-based biomarkers for Alzheimer's disease using whole-blood assays.
Signed a letter of intent for potential commercial collaboration to secure access to external assays for measuring aggregated amyloid‑β and α‑synuclein in blood.
Regulatory authorisation granted by the UK regulator for clinical evaluation of a repurposed-drug combination targeting amyloid pathology.
Collaboration to investigate epigenetic mechanisms relevant to Alzheimer's disease risk and earlier interventions.